Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.480 -0.040 (-1.14%)
Streaming Delayed Price Updated: 1:34 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AbCellera Reports Q3 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Earnings Preview: AbCellera Biologics ↗
 
Via Benzinga
News headline image
Recap: AbCellera Biologics Q1 Earnings ↗
 
Via Benzinga
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
News headline image
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects ↗
Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL),  
Via Benzinga
News headline image
3 AI Stocks You’ll Regret Not Buying Soon ↗
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
News headline image
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition. 
Via Benzinga
News headline image
Apple, Fortinet, Microchip Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript ↗
ABCL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AbCellera Reports Q2 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
News headline image
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom ↗
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider. 
Via InvestorPlace
News headline image
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
7 Growth Stocks That Could Double Your Money in 2023 ↗
For investors that really want to roll the dice, these are the enticing growth stocks that could double your money. 
Via InvestorPlace
News headline image
AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript ↗
ABCL earnings call for the period ending March 31, 2023. 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.